Who are Macitentan/Tadalafil FDC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FDC macitentan/tadalafil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/macitentan-tadalafil-fdc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Macitentan/Tadalafil FDC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Macitentan/Tadalafil FDC (Macitentan/Tadalafil FDC) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination. Area: Cardiovascular.

phase 3 Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination Endothelin receptor A and B / Phosphodiesterase-5 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Macitentan/Tadalafil FDC (Macitentan/Tadalafil FDC) — Actelion. This fixed-dose combination blocks endothelin-1 receptors (via macitentan) to reduce pulmonary vascular resistance while simultaneously inhibiting phosphodiesterase-5 (via tadalafil) to promote vasodilation in the pulmonary circulation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Macitentan/Tadalafil FDC TARGET	Macitentan/Tadalafil FDC	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5
FDC macitentan/tadalafil	FDC macitentan/tadalafil	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination class)

Actelion · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Macitentan/Tadalafil FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/macitentan-tadalafil-fdc. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing